{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-082470","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2022-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.702263+00:00","generated_at":"2026-06-24T09:01:52.841015+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rigel files patent lawsuit against Annora to block generic TAVALISSE","bullets":["Filed suit in U.S. District Court for New Jersey against Annora Pharma, Hetero Labs, and Hetero USA for patent infringement.","Lawsuit responds to Annora's ANDA seeking FDA approval for a generic version of TAVALISSE (fostamatinib).","Annora sent Paragraph IV Notice Letter in June 2022 alleging the five asserted patents are invalid or not infringed.","Asserted patents: 7,449,458, 8,263,122, 8,652,492, 8,771,648, and 8,951,504 listed in the FDA Orange Book.","Rigel seeks equitable relief to enjoin Annora from infringing the patents covering TAVALISSE."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-082470","json":"https://secwatch.observer/filing/0001104659-22-082470.json","markdown":"https://secwatch.observer/filing/0001104659-22-082470.md","text":"https://secwatch.observer/filing/0001104659-22-082470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465922082470/0001104659-22-082470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465922082470/tm2221725d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T09:01:52.841015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}